A U.S. Food and Drug Administration (FDA) panel has recommended approval of the MS drug fampridine.

According to drugmaker Novartis, their experimental MS drug FTY720 reduces relapses and disability progression.

Five Democrats voted with all of the panel’s Republicans in opposing the inclusion of the government-run option in the bill in what is expected to be the first of several battles in Congress over the public option.